Loading…
Loading…
Decision Diagnostics (OTCMKTS:DECN - Get Free Report) and 10x Genomics (NASDAQ: TXG - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings. Profitability This table compares Decision Diagnostics and 10x
Privia Health Group (NASDAQ: PRVA - Get Free Report) and Decision Diagnostics (OTCMKTS:DECN - Get Free Report) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends. Volatility and Risk Privia Health Group has
Strata Skin Sciences (NASDAQ: SSKN - Get Free Report) and Decision Diagnostics (OTCMKTS:DECN - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations. Valuation and Earnings This table compares Strata
New York, New York--(Newsfile Corp. - March 14, 2021) - Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ("Decision Diagnostics" or the "Company") (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00418, is on behalf of a class consisting of all persons and entities other than Defendants that purchased...
NEW YORK, March 12, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ("Decision Diagnostics" or the "Company") (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00418, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Decision Diagnostics securities between March 3, 2020 and December 17, 2020, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
NEW YORK, March 3, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ("Decision Diagnostics" or the "Company") (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District...
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Decision Diagnostics Corp. ("Decision" or "the Company") (OTC: DECN) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Decision securities between March 3, 2020 and December 17, 2020, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/decn. This cla
PHILADELPHIA, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Decision Diagnostics Corp. (“Decision Diagnostics”) (OTC: DECN) on behalf of the company's stockholders.
No recent filings indexed.